Health Care · Pharmaceuticals

Johnson & Johnson JNJ

$265.85-2.19 (-0.82%)delayed quote · as of 2026-09-01 02:30 UTC

Open JNJ in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$640.7B

Previous close

$268.04

Volume

7.7M

52-week range

$173.33 – $276.47

Verdict

Reading JNJ’s filed statements…

Continue with JNJ in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.

Health Care · Pharmaceuticals

Johnson & Johnson JNJ

$265.85-2.19 (-0.82%)delayed quote · as of 2026-09-01 02:30 UTC

Open JNJ in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$640.7B

Previous close

$268.04

Volume

7.7M

52-week range

$173.33 – $276.47

Verdictconfidence 96% · high

Growth, Health and Momentum stand out; execution flashes caution.

4 of 5 dimensions score well; execution flashes caution.

Value603/5 checks

Growth1005/5 checks

Execution251/4 checks

Health804/5 checks

Momentum1005/5 checks

Fair-value estimate $287.68 per share (2-stage FCF · individual beta · 10Y Rf 4.7% · term g 2.75%) — the price sits 8% below it.

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

30.8

P/E FWD

21.6

EV/EBITDA TTM

19.3

PEG

1.58

FCF yield TTM

3.5%

Growth

Revenue 3y

+5.6%/yr

Revenue YoY

+6.0%

Expected EPS

+42.8%

Execution

Piotroski F

4 / 9

ROIC

—

Gross margin

67.9%

Health

Altman Z

4.94

Current ratio

1.03

Debt/equity

0.59

Momentum

vs 50-day

+10.5%

vs 200-day

+32.5%

52-wk range

90%

FY 2025: revenue $94.2B · net income $26.8B · free cash flow $19.7B (SEC EDGAR filings)

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-09-01 02:30 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading JNJ’s filed statements…

Continue with JNJ in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account